MilliporeSigma
  • Home
  • Search Results
  • Combined treatment with GH and IGF-I: additive effect on cortical bone mass but not on linear bone growth in female rats.

Combined treatment with GH and IGF-I: additive effect on cortical bone mass but not on linear bone growth in female rats.

Endocrinology (2014-09-23)
Katja Sundström, Therese Cedervall, Claes Ohlsson, Cecilia Camacho-Hübner, Lars Sävendahl
ABSTRACT

The growth-promoting effect of combined therapy with GH and IGF-I in normal rats is not known. We therefore investigated the efficacy of treatment with recombinant human (rh)GH and/or rhIGF-I on longitudinal bone growth and bone mass in intact, prepubertal, female Sprague-Dawley rats. rhGH was injected twice daily sc (5 mg/kg·d) and rhIGF-I continuously infused sc (2.2 or 4.4 mg/kg·d) for 28 days. Longitudinal bone growth was monitored by weekly x-rays of tibiae and nose-anus length measurements, and tibial growth plate histomorphology was analyzed. Bone mass was evaluated by peripheral quantitative computed tomography. In addition, serum levels of IGF-I, rat GH, acid labile subunit, IGF binding protein-3, 150-kDa ternary complex formation, and markers of bone formation and degradation were measured. Monotherapy with rhGH was more effective than rhIGF-I (4.4 mg/kg·d) to increase tibia and nose-anus length, whereas combined therapy did not further increase tibia, or nose-anus, lengths or growth plate height. In contrast, combined rhGH and rhIGF-I (4.4 mg/kg·d) therapy had an additive stimulatory effect on cortical bone mass vs rhGH alone. Combined treatment with rhGH and rhIGF-I resulted in markedly higher serum IGF-I concentrations vs rhGH alone but did not compromise the endogenous secretion of GH. We conclude that rhIGF-I treatment augments cortical bone mass but does not further improve bone growth in rhGH-treated young, intact, female rats.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Phenol, contains hypophosphorous as stabilizer, loose crystals, ACS reagent, ≥99.0%
Sigma-Aldrich
Phenol, unstabilized, purified by redistillation, ≥99%
Sigma-Aldrich
Phenol solution, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, BioReagent, for molecular biology
Sigma-Aldrich
Phenol, BioXtra, ≥99.5% (GC)
Sigma-Aldrich
Phenol solution, Saturated with 0.1 M citrate buffer, pH 4.3 ± 0.2, BioReagent, for molecular biology
Sigma-Aldrich
Phenol, unstabilized, ReagentPlus®, ≥99%
Sigma-Aldrich
Phenol, ≥99%
Supelco
Phenol, PESTANAL®, analytical standard
Sigma-Aldrich
Sodium acetate trihydrate, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
Phenol, ≥96.0% (calc. on dry substance, T)
Sigma-Aldrich
Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, ≥99.5% (GC), crystalline (detached)
Sigma-Aldrich
Phenol, BioUltra, for molecular biology, TE-saturated, ~73% (T)
Sigma-Aldrich
Phenol, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (GC)
Sigma-Aldrich
Phenol, puriss. p.a., ACS reagent, reag. Ph. Eur., 99.0-100.5%
Supelco
Phenol solution, 100 μg/mL in acetonitrile, PESTANAL®, analytical standard
Sigma-Aldrich
5α-Androstan-17β-ol-3-one, ≥97.5%
Sigma-Aldrich
Sodium acetate trihydrate, meets USP testing specifications
Sigma-Aldrich
Sodium acetate trihydrate, BioXtra, ≥99.0%
Sigma-Aldrich
Citric acid monohydrate, reagent grade, ≥98% (GC/titration)
Sigma-Aldrich
Citric acid monohydrate, BioXtra, ≥99.5%
Sigma-Aldrich
Citric acid monohydrate, ACS reagent, ≥99.0%
Sigma-Aldrich
Phenol, for molecular biology
Supelco
Phenol, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
5α-Androstan-17β-ol-3-one, VETRANAL®, analytical standard
Millipore
Bifido Selective Supplement B, suitable for microbiology
Supelco
Phenol solution, 5000 μg/mL in methanol, certified reference material
Supelco
Phenol solution, certified reference material, 500 μg/mL in methanol
Citric acid monohydrate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Phenol, natural, 97%, FG